Novartis AG
THERAPEUTIC REGIMENS FOR CHIMERIC ANTIGEN RECEPTOR THERAPIES
Last updated:
Abstract:
The invention provides a method of treating an adult subject having a hematological cancer, comprising administering to the subject selected dosage regimens comprising a plurality of immune effector cells expressing a CAR molecule.
Status:
Application
Type:
Utility
Filling date:
15 May 2019
Issue date:
19 Mar 2020